<DOC>
	<DOCNO>NCT00004442</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine effectiveness oral bile acid therapy cholic acid , chenodeoxycholic acid , ursodeoxycholic acid patient peroxisomal disorder involve impaired primary bile acid synthesis . II . Determine whether suppression synthesis atypical bile acid enrichment bile acid pool regimen effective treat patient population improve quality life .</brief_summary>
	<brief_title>Study Bile Acids Patients With Peroxisomal Disorders</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive oral cholic acid oral chenodeoxycholic acid day 1 . On day 4 , patient receive oral cholic ursodeoxycholic acid . Patients assess 3 6 month liver function response , neurologic status , nutritional status . Patients receive treatment disease progression unacceptable toxic effect observe . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<mesh_term>Peroxisomal Disorders</mesh_term>
	<mesh_term>Refsum Disease</mesh_term>
	<mesh_term>Refsum Disease , Infantile</mesh_term>
	<mesh_term>Zellweger Syndrome</mesh_term>
	<mesh_term>Chenodeoxycholic Acid</mesh_term>
	<mesh_term>Cholic Acids</mesh_term>
	<criteria>Biochemically prove peroxisomal disorder , include : Zellweger syndrome PseudoZellweger syndrome Neonatal adrenoleukodystrophy Bifunctional enzyme deficiency Infantile Refsum 's disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>November 2000</verification_date>
	<keyword>Zellweger syndrome</keyword>
	<keyword>adrenoleukodystrophy</keyword>
	<keyword>bifunctional enzyme deficiency</keyword>
	<keyword>inborn error metabolism</keyword>
	<keyword>infantile Refsum 's disease</keyword>
	<keyword>peroxisomal disorder</keyword>
	<keyword>pseudo-Zellweger syndrome</keyword>
	<keyword>rare disease</keyword>
	<keyword>sphingolipidoses</keyword>
</DOC>